5 Undervalued European Stocks to Buy

3. BioNTech SE (NASDAQ:BNTX)

Latest Trailing P/E Ratio: 3.8

BioNTech SE (NASDAQ:BNTX) is a biotechnology company that develops treatments for different kinds of cancers, tumors, tuberculosis, and malaria among others. Its shares are rated a Buy on average and have an approximate $58 upside. The firm announced in late June that it will start Phase 3 trials for a lung cancer treatment.

22 of the 943 hedge funds had invested in BioNTech SE (NASDAQ:BNTX) during Q1 2023. Out of these, the company’s biggest shareholder is Jim Simons’ Renaissance Technologies since it owns 509,951 shares that are worth $63 million.

Follow Biontech Se (NASDAQ:BNTX)